Zobrazeno 1 - 10
of 24
pro vyhledávání: '"JuYi Wen"'
Publikováno v:
Chinese Journal of Lung Cancer, Vol 23, Iss 5, Pp 306-313 (2020)
Background and objective Flubendazole is an anthelmintic and categorized in benzimidazole. Previous evidence indicates its suppression on proliferation of colon cancer and breast cancer cells. Our study aims to explore the effects of flubendazole on
Externí odkaz:
https://doaj.org/article/73a60ad8581a4bf79d6facbc0812a2bb
Autor:
Rui Wan, Xiaorong Dong, Qun Chen, Yan Yu, Shujun Yang, Xiaochun Zhang, Guojun Zhang, Yueyin Pan, Sanyuan Sun, Chengzhi Zhou, Wei Hong, Hui Zhao, Lei Yang, Linian Huang, Rong Wu, Aimin Zang, Rui Ma, Lin Wu, Dongqing Lv, Xiuhua Fu, Jianguo Han, Wenxin Li, Jianchun Duan, Kai Wang, Ou Jiang, Yinglan Chen, Zhongliang Guo, Hongjun Gao, Juyi Wen, Shubin Wang, Enfeng Zhao, Gaofeng Li, Lu Yue, Li Liang, Aiping Zeng, Xiaoshan Wang, Yuxi Zhu, Hongming Pan, Zhaoxia Dai, Weineng Feng, Guofang Zhao, Chuan Lin, Chong Li, Na Li, Yangyi Bao, Yinyin Li, Yanjun Su, Min Zhao, Haohui Fang, Yulong Zhu, Yu Zhang, Lieming Ding, Yang Wang, Xiaobin Yuan, Jie Wang
Publikováno v:
EClinicalMedicine, Vol 42, Iss , Pp 101187- (2021)
Background: We compared the efficacy, safety, and immunogenicity of MIL60 with reference bevacizumab as first-line treatment in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) in this phase 3, randomized, double-bl
Externí odkaz:
https://doaj.org/article/fdbc7c412b564497a8805b161236dd76
Autor:
Jihua Yang, Wenjia Shi, Zhen Yang, Hang Yu, Miaoyu Wang, Yuanhui Wei, Juyi Wen, Wei Zheng, Peng Zhang, Wei Zhao, Liang’an Chen
Publikováno v:
Translational Lung Cancer Research. 12:808-823
Autor:
XiangFei Zhao, RuGang Zhao, JuYi Wen, Xia Zhang, ShanShan Wu, Juan Fang, JunPeng Ma, Wei Zheng, XinHong Zhang, ZeJun Lu, LiPin Gao, Yi Hu
Publikováno v:
Anti-Cancer Drugs; Oct2023, Vol. 34 Issue 9, p1018-1024, 7p
Autor:
Wei, Zheng, Jihua, Yang, Juyi, Wen, Junzhao, Sun, Jing, Wang, Xinhong, Zhang, Xia, Zhang, Xiangfei, Zhao, Henghu, Fang, Qi, Zhu, Shanshan, Wu, Zejun, Lu, Heng, Sun, Rugang, Zhao, Siyuan, Huai, Lipin, Gao, Yongzhen, Liu, Jingjiao, Li, Gaowa, Guan, Wei, Yang, Yi, Hu
Publikováno v:
Translational Cancer Research. 11:559-568
The aim of this study was to evaluate the effect of ligustrazine on the apoptosis of A549 cells and clarify the mechanism of ligustrazine-induced apoptosis.Ligustrazine was prepared with medium according to the gradient concentration. Based on a cyto
Autor:
XiangFei, Zhao, RuGang, Zhao, JuYi, Wen, Xia, Zhang, ShanShan, Wu, Juan, Fang, JunPeng, Ma, Wei, Zheng, XinHong, Zhang, ZeJun, Lu, LiPin, Gao, Yi, Hu
Publikováno v:
Anti-Cancer Drugs.
By exploring the effects of an antiangiogenic small molecule drug named anlotinib on the levels of myeloid-derived suppressor cells (MDSCs) in a mouse xenograft model of lung cancer, the role of anti-angiogenesis in remodeling the immune microenviron
Publikováno v:
American journal of translational research. 14(11)
The molecular mechanisms underlying tumor progression and drug resistance in colorectal cancer remain to be fully understood. Recent studies have reported a pro-tumorigenic role of an amino acid oxidase named interleukin-4-induced-1 (IL4I1). Here, we
Autor:
Xiaoshan Wang, Lieming Ding, Yuxi Zhu, Hui Zhao, Linian Huang, Weineng Feng, Guofang Zhao, Yanjun Su, Enfeng Zhao, Na Li, Yulong Zhu, Dongqing Lv, Xiuhua Fu, Hongjun Gao, Aimin Zang, Rui Wan, Gaofeng Li, Rong Wu, Rui Ma, Lu Yue, Yinyin Li, Zhaoxia Dai, Yu Zhang, Chong Li, Wei Hong, Qun Chen, Yueyin Pan, Jie Wang, Chengzhi Zhou, Lei Yang, Shujun Yang, Aiping Zeng, Jianchun Duan, Juyi Wen, Jianguo Han, Hongming Pan, Guojun Zhang, Sanyuan Sun, Zhongliang Guo, Yan Yu, Yang Wang, Yinglan Chen, Shubin Wang, Min Zhao, Kai Wang, Haohui Fang, Xiaobin Yuan, Xiaorong Dong, Yangyi Bao, Lin Wu, Chuan Lin, Li Liang, Ou Jiang, Xiaochun Zhang, Wenxin Li
Publikováno v:
EClinicalMedicine
EClinicalMedicine, Vol 42, Iss, Pp 101187-(2021)
EClinicalMedicine, Vol 42, Iss, Pp 101187-(2021)
Background We compared the efficacy, safety, and immunogenicity of MIL60 with reference bevacizumab as first-line treatment in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) in this phase 3, randomized, double-bli
Autor:
Qingyi Wei, Xiaomeng Wang, Zhensheng Liu, Ritsuko Komaki, Lili Wang, Daniel R. Gomez, Ting Xu, Hongliang Liu, Juyi Wen, Ning Gu, Zhongxing Liao
Publikováno v:
Journal of Thoracic Oncology. 13:660-675
Introduction Autophagy not only plays an important role in the progression of cancer but is also involved in tissue inflammatory response. However, few published studies have investigated associations between functional genetic variants of autophagy-
Publikováno v:
Biochemical and biophysical research communications. 500(3)
Tumor metastasis and recurrence are the primary contributors to poor prognosis in patients with hepatocellular carcinoma (HCC). The epithelial-mesenchymal transition (EMT) of tumor cells is the predominant mechanism of HCC progression. XBP1s is a new